Literature DB >> 2504511

Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.

L W Gimple1, H K Gold, R C Leinbach, B S Coller, W Werner, T Yasuda, J A Johns, A A Ziskind, D Finkelstein, D Collen.   

Abstract

The purpose of this study was to correlate bleeding complications during and after treatment with recombinant tissue-type plasminogen activator (rt-PA) with serial template bleeding time measurements, with ADP-induced platelet aggregation, with clinical characteristics, and with hemostatic parameters. Fifty-two of 55 consecutive patients with acute myocardial infarction and template bleeding times (Ivy method) of less than 9.5 minutes were treated with rt-PA in a total dose of 55-212 mg (mean, 109 mg) over 90 to 360 minutes (median, 240 minutes) combined with heparin. The mean bleeding time was significantly prolonged at 90 minutes (from 5.0 +/- 1.9 to 8.2 +/- 4.3 minutes, p less than 0.0001) but returned toward baseline after 4 hours (from a median of 8.0 to 7.0 minutes, p less than 0.05). Thirteen patients (25%) suffered relatively minor but spontaneous bleeding that did not correlate with age, hypertension, smoking, partial thromboplastin time, platelet count, ADP-induced platelet aggregation, steady-state rt-PA level, or extent of fibrinogen degradation. In multivariate analysis, only the 90-minute bleeding time correlated with spontaneous bleeding (p = 0.01). Prolongation of the 90-minute bleeding time to greater than or equal to 9 minutes, which occurred in 21 patients, correlated with spontaneous bleeding with a sensitivity of 69% (95% confidence interval, 39-90%) and a specificity of 69% (95% confidence interval, 52-83%). Retrospective analysis revealed that in 14 patients taking aspirin, the bleeding time at 90 minutes was significantly more prolonged (p less than 0.05) and spontaneous bleeding significantly more frequent (p less than 0.01) than in patients not taking aspirin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504511     DOI: 10.1161/01.cir.80.3.581

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat.

Authors:  S M Lavelle; M MacIomhair
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

2.  Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.

Authors:  Erik I Tucker; Ulla M Marzec; Michelle A Berny; Sawan Hurst; Stuart Bunting; Owen J T McCarty; András Gruber; Stephen R Hanson
Journal:  Sci Transl Med       Date:  2010-06-23       Impact factor: 17.956

3.  Bleeding complications after thrombolysis.

Authors:  M I Khalid
Journal:  BMJ       Date:  1993-07-24

Review 4.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

Review 5.  Platelet function tests: a comparative review.

Authors:  Rita Paniccia; Raffaella Priora; Agatina Alessandrello Liotta; Rosanna Abbate
Journal:  Vasc Health Risk Manag       Date:  2015-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.